Hew, M., Gillman, A., Rimmer, J., Katsoulotos, G. P., Cook, M., Yang, I., Katelaris, C., Bowler, S., Langton, D., Wright, C., Bint, M., Yozghatlian, V., Sutherland, M., Powell, H., McDonald, V. M., Gibson, P. G., Wark, P., Bowden, J., Guo, M., Reddel, H. K., Jenkins, C., Marks, G. B., Thien, F.. Wiley-Blackwell; 2016. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.

Gibson, P. G., Reddel, H., Katsoulotos, G. P., Cook, M., Yang, I., Katelaris, C., Bowler, S., Langton, D., Robinson, P., Wright, C., Yozghatlian, V., Burgess, S., McDonald, V. M., Sivakumaran, P., Jaffe, A., Bowden, J., Wark, P. A. B., Yan, K. Y., Kritikos, V., Peters, M., Hew, M., Aminazad, A., Bint, M., Marks, G., Guo, M., Jenkins, C., Gillman, A., Upham, J., Sutherland, M., Rimmer, J., Thien, F.. Wiley-Blackwell Publishing; 2016. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.